Skip to main content
Erschienen in: CardioVasc 6/2018

10.12.2018 | Fortbildung

Techniken, Indikationen, Ergebnisse

Stenting der peripheren Arterien

verfasst von: Dr. Klaus Amendt, Dr. Martin Sigl

Erschienen in: CardioVasc | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei Patienten mit symptomatischer arterieller Verschlusskrankheit wird die perkutane Behandlung als „first line“-Therapie durchgeführt. Nach Rekanalisierung und Dilatation der arteriellen Obstruktionen werden zur Stabilisierung Gefäßstützen implantiert, was zu einem chronischen Trauma der Gefäßwand führt, mit Restenose und Reverschluss als Folge. Aktuelle Entwicklungen der Ballon- und Stent-Technologie führen zu zunehmend besseren Ergebnissen.
Literatur
1.
Zurück zum Zitat Krankenberg H, Schlüter M, Steinkamp HJ et al. Nitinol Stent Implantation Versus Percutaneous Transluminal angioplasty in Superficila Femoral Artery Lesions up to 10 cm in Length. The Femoral Artery Stenting Trial (FAST). Circulation. 2007;116–124 Krankenberg H, Schlüter M, Steinkamp HJ et al. Nitinol Stent Implantation Versus Percutaneous Transluminal angioplasty in Superficila Femoral Artery Lesions up to 10 cm in Length. The Femoral Artery Stenting Trial (FAST). Circulation. 2007;116–124
2.
Zurück zum Zitat Scheinert D, Scheinert S, Sax J et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–5CrossRef Scheinert D, Scheinert S, Sax J et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–5CrossRef
3.
Zurück zum Zitat Matsumura JS, Yamanouchi D, Goldstein JA et al. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol Stent System II (DURABULITY II). J Vasc Surg. 2013;58:73–83CrossRef Matsumura JS, Yamanouchi D, Goldstein JA et al. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol Stent System II (DURABULITY II). J Vasc Surg. 2013;58:73–83CrossRef
4.
Zurück zum Zitat Vardi M, Novack V, Pencina et al. Safety and Efficacy Metrics for Primary Nitinol Stenting in Femoropopliteal Occlusive Disease: A Meta-analysis and critical Examination of Current Methodologies. Catheter Cardiovasc Interv. 2014;83:975–83CrossRef Vardi M, Novack V, Pencina et al. Safety and Efficacy Metrics for Primary Nitinol Stenting in Femoropopliteal Occlusive Disease: A Meta-analysis and critical Examination of Current Methodologies. Catheter Cardiovasc Interv. 2014;83:975–83CrossRef
5.
Zurück zum Zitat Werner M, Paetzold A, Banning-Eichenseer U et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014;10(7):861–8CrossRef Werner M, Paetzold A, Banning-Eichenseer U et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014;10(7):861–8CrossRef
6.
Zurück zum Zitat Tepe G, Zeller T, Albrecht T et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99CrossRef Tepe G, Zeller T, Albrecht T et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99CrossRef
7.
Zurück zum Zitat Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen. Drug Eluting Balloons (DEB) bei pAVK — Nutzenbewertung und Indikationskriterien. Version 2.0 vom 28.4.2017. https://www.mds-ev.de Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen. Drug Eluting Balloons (DEB) bei pAVK — Nutzenbewertung und Indikationskriterien. Version 2.0 vom 28.4.2017. https://​www.​mds-ev.​de
8.
Zurück zum Zitat Schneider P. At VIVA 2017. Four-Year Results of the INPACT.SFA TRIAL. Drug-Coated Balloon Catheter vs an Uncoated Balloon Catheter in Femoropopliteal Lesions. DAIC 2017: September 14 Schneider P. At VIVA 2017. Four-Year Results of the INPACT.SFA TRIAL. Drug-Coated Balloon Catheter vs an Uncoated Balloon Catheter in Femoropopliteal Lesions. DAIC 2017: September 14
9.
Zurück zum Zitat Duda SH, Bosiers M, Lammer J et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331–8CrossRef Duda SH, Bosiers M, Lammer J et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331–8CrossRef
10.
Zurück zum Zitat Dake MD, Ansel GM, Jaff MR et al. Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504CrossRef Dake MD, Ansel GM, Jaff MR et al. Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504CrossRef
11.
Zurück zum Zitat Gray WA, Keirse K, Soga Y et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018; https://doi.org/10.1016/S0140-6736(18)32262-1 Gray WA, Keirse K, Soga Y et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018; https://​doi.​org/​10.​1016/​S0140-6736(18)32262-1
12.
Zurück zum Zitat Davaine JM, Querat J, Kaladji A et al. Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry. Eur J Vasc Endovasc Surg. 2015;50(5):631–7CrossRef Davaine JM, Querat J, Kaladji A et al. Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry. Eur J Vasc Endovasc Surg. 2015;50(5):631–7CrossRef
13.
Zurück zum Zitat Goueffic Y et al. BATTLE: Randomised controlled trial at one year-paclitaxel-eluting stent vs. bare metal stent. Late-breaking trials and first-on-podium presentations: Vortrag beim Charing Cross International Symposium, 24. April 2018, London Goueffic Y et al. BATTLE: Randomised controlled trial at one year-paclitaxel-eluting stent vs. bare metal stent. Late-breaking trials and first-on-podium presentations: Vortrag beim Charing Cross International Symposium, 24. April 2018, London
14.
Zurück zum Zitat Liistro F. Preliminary data on DRASTICO RCT comparing DCB vs. DES in the treatment of FemPop disease in real world. Leipzig Interventional Course. 24. Januar 2017; https://linc2017.cncptdlx.com/media/1430_Francesco_Liistro_24_01_2017_Room_6_-_Speakers_corner.pdf Liistro F. Preliminary data on DRASTICO RCT comparing DCB vs. DES in the treatment of FemPop disease in real world. Leipzig Interventional Course. 24. Januar 2017; https://​linc2017.​cncptdlx.​com/​media/​1430_​Francesco_​Liistro_​24_​01_​2017_​Room_​6_​-_​Speakers_​corner.​pdf
15.
Zurück zum Zitat Scheinert D. Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions. Leipzig Interventional Course. 31. Januar 2018; https://linc2018.cncptdlx.com/media/1055_Dierk_Scheinert_31_01_2018_Room_5_-_Global_Expert_Exchange.pdf Scheinert D. Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions. Leipzig Interventional Course. 31. Januar 2018; https://​linc2018.​cncptdlx.​com/​media/​1055_​Dierk_​Scheinert_​31_​01_​2018_​Room_​5_​-_​Global_​Expert_​Exchange.​pdf
16.
Zurück zum Zitat Hong SJ, Ko YG, Shin DH et al. Outcomes of Spot Stenting Versus Long Stenting After Intentional Subintimal Approach for Long Chronic Total Occlusions of the Femoropopliteal Artery. J Am Coll Cardiol Interv. 2015;8:472–80CrossRef Hong SJ, Ko YG, Shin DH et al. Outcomes of Spot Stenting Versus Long Stenting After Intentional Subintimal Approach for Long Chronic Total Occlusions of the Femoropopliteal Artery. J Am Coll Cardiol Interv. 2015;8:472–80CrossRef
17.
Zurück zum Zitat Ko YG. Comparison of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE). Leipzig Interventional Course. 31. Januar 2018; https://linc2018.cncptdlx.com/media/1400_Young-Guk_Ko_31_01_2018_Room_7_-_Speakers_corner.pdf Ko YG. Comparison of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE). Leipzig Interventional Course. 31. Januar 2018; https://​linc2018.​cncptdlx.​com/​media/​1400_​Young-Guk_​Ko_​31_​01_​2018_​Room_​7_​-_​Speakers_​corner.​pdf
18.
Zurück zum Zitat Sigl M, Dudeck O, Jung J et al. Multiple stent delivery system Multi-LOC, a new technology for spot-stenting of femoropopliteal artery-proof of concept in a preclinical large animal model. Vasa. 2017;46:446–51CrossRef Sigl M, Dudeck O, Jung J et al. Multiple stent delivery system Multi-LOC, a new technology for spot-stenting of femoropopliteal artery-proof of concept in a preclinical large animal model. Vasa. 2017;46:446–51CrossRef
19.
Zurück zum Zitat Amendt K, Beschorner U, Waliszewsky M et al. First clinical experience with the Multi-LOC multiple stent delivery system for fokal stenting in long femoro-popliteal lesions. Vasa. 2017;46:452–61CrossRef Amendt K, Beschorner U, Waliszewsky M et al. First clinical experience with the Multi-LOC multiple stent delivery system for fokal stenting in long femoro-popliteal lesions. Vasa. 2017;46:452–61CrossRef
20.
Zurück zum Zitat Amendt K. All Comers Study with the VascuFlex Multi-LOC spot stenting device: 12-month results. Leipzig Interventional Course. 30. Januar 2018; https://linc2018.cncptdlx.com/media/1045_Klaus_Amendt_30_01_2018_Room_1_-_Main_Arena_1_v2.pdf Amendt K. All Comers Study with the VascuFlex Multi-LOC spot stenting device: 12-month results. Leipzig Interventional Course. 30. Januar 2018; https://​linc2018.​cncptdlx.​com/​media/​1045_​Klaus_​Amendt_​30_​01_​2018_​Room_​1_​-_​Main_​Arena_​1_​v2.​pdf
Metadaten
Titel
Techniken, Indikationen, Ergebnisse
Stenting der peripheren Arterien
verfasst von
Dr. Klaus Amendt
Dr. Martin Sigl
Publikationsdatum
10.12.2018
Verlag
Springer Medizin
Erschienen in
CardioVasc / Ausgabe 6/2018
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI
https://doi.org/10.1007/s15027-018-1482-0

Weitere Artikel der Ausgabe 6/2018

CardioVasc 6/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.